Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib

BACKGROUND: Chemoresistance often limits the success of the pharmacological treatment in acute myeloid leukemia (AML) patients. Although positive results have been obtained with tyrosine kinase inhibitors (TKIs), such as sorafenib, especially in patients with Fms-like tyrosine kinase 3 (FLT3)-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Macias, Rocio I.R., Sánchez-Martín, Anabel, Rodríguez-Macías, Gabriela, Sánchez-Abarca, Luis I., Lozano, Elisa, Herraez, Elisa, Odero, Maria D., Díez-Martín, José L., Marin, Jose J.G., Briz, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033373/
https://www.ncbi.nlm.nih.gov/pubmed/29983874
http://dx.doi.org/10.18632/oncotarget.25494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033373/
https://www.ncbi.nlm.nih.gov/pubmed/29983874
http://dx.doi.org/10.18632/oncotarget.25494

Ejemplares similares